The Irritable Bowel Syndrome Market is being driven by Increasing prevalence of IBS
The Irritable Bowel Syndrome Market is expected to grow at a CAGR of 9.3% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 1931.9 million. The global irritable bowel syndrome (IBS) market is witnessing a significant trend with an increasing number of drug approvals aimed at managing this condition. Regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have expedited the approval process for innovative therapies designed to alleviate IBS symptoms, reflecting the growing recognition of the condition's substantial impact on patients' quality of life and the urgent need for effective treatment options. Notably, in June 2023, Ironwood Pharmaceuticals announced the FDA's approval of a new indication for Linzess (linaclotide) for treating functional constipation in pediatric patients aged 6 to 17 years, further expanding the market landscape.
Get more information on Irritable Bowel Syndrome Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
209 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.3% |
|
Market growth 2024-2028 |
USD 1931.9 million |
|
Market structure |
market_structure.ucfirst |
|
YoY growth 2023-2024(%) |
9.0 |
|
Key countries |
US, China, Germany, Japan, UK, India, France, Canada, Australia, and Brazil |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Irritable Bowel Syndrome (IBS) market encompasses various interventions for managing symptoms of this chronic digestive disorder. These include the FODMAP and Low-FODMAP diet, antidiarrheal medications, fiber supplements, and lifestyle modifications such as physical activity and food journaling. Other approaches include addressing food intolerances and allergies, manipulating the gut microbiome through probiotics and prebiotics, and targeting gastrointestinal motility and visceral hypersensitivity. Patient-reported outcomes (PROs) and healthcare utilization data are crucial in disease management programs, which may incorporate telehealth platforms, mHealth apps, wearable technology, genetic testing, precision medicine, drug repurposing, and clinical trials.
The Irritable Bowel Syndrome (IBS) market encompasses businesses involved in the research and development (R&D) or production of IBS treatments, medications, therapies, and management tools. According to Technavio, the global pharmaceuticals market, which includes these entities, is projected to expand due to several factors. One significant driver is the increasing aging population. By 2050, approximately one-quarter of the US population and by 2030 in Europe are predicted to be over 60 years old. This demographic shift will fuel the demand for IBS treatments, medications, and diagnostic tools as older adults are more susceptible to IBS symptoms. The global pharmaceuticals market size is calculated based on the collective revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
